Cytotoxicity of TAK-1 to freshly isolated leukemia cells
| Target Cells (donor) . | HLA-A24 . | WT1/GAPDH3-150 . | % Specific Lysis3-151 . | ||
|---|---|---|---|---|---|
| 10:1 . | 5:1 . | 2.5:1 . | |||
| Leukemia cells | |||||
| AML, M2 (S. M.) | + | 0.29 | 42.1 | 29.9 | 20.0 |
| AML, M2 (M. M.) | + | 0.23 | 29.3 | 19.9 | 11.1 |
| AML, M2 (I. K.) | + | 0.47 | 51.7 | 43.3 | 36.2 |
| AML, M4 (K. O.) | + | 0.22 | 39.7 | 24.7 | 18.8 |
| AML, M4 (T. F.) | + | 0.19 | 40.3 | 32.9 | 27.5 |
| AML, M5 (T. O.) | + | ND | 15.4 | 10.5 | 7.0 |
| AML, M5 (F. O.) | + | 0.15 | 0.9 | 0.9 | 0.1 |
| ALL, L2 (K. I.) | + | ND | 32.1 | 27.3 | 13.5 |
| ALL, L2 (M. H.) | + | 0.34 | 3.9 | 1.1 | 0.8 |
| AML, M2 (E. O.) | − | <0.01 | 0.1 | 0.8 | 0 |
| AML, M3 (S. N.) | − | ND | 2.9 | 0.5 | 1.2 |
| AML, M4 (K. N.) | − | 0.30 | 0.7 | 0.4 | 0.9 |
| AML, M5 (M. O.) | − | 0.29 | 1.8 | 1.0 | 0.5 |
| ALL, L1 (N. Y.) | − | 0.43 | 1.5 | 0.5 | 1.0 |
| ALL, L2 (T. M.) | − | 0.32 | 1.3 | 0.5 | 0.2 |
| ALL, L2 (Y. I.) | − | ND | 0.4 | 0.5 | 1.3 |
| Normal foreskin fibroblasts | |||||
| #1 (A. S.) | + | <0.01 | 0.8 | 0.6 | 0.2 |
| #2 (T. A.) | + | <0.01 | 1.6 | 0.9 | 1.1 |
| #3 (Y. N.) | + | <0.01 | 0.7 | 1.0 | 0.4 |
| #4 (N. G.) | − | <0.01 | 0.2 | 0.7 | 1.2 |
| #5 (M. Y.) | − | <0.01 | 0.8 | 0 | 1.9 |
| Normal PBMCs | |||||
| #1 (H. O.) | + | <0.01 | 0.6 | 0.5 | 0.1 |
| #2 (J. A.) | + | <0.01 | 1.4 | 0.2 | 0.8 |
| #3 (T. N.) | − | <0.01 | 0.1 | 0.5 | 0.7 |
| Target Cells (donor) . | HLA-A24 . | WT1/GAPDH3-150 . | % Specific Lysis3-151 . | ||
|---|---|---|---|---|---|
| 10:1 . | 5:1 . | 2.5:1 . | |||
| Leukemia cells | |||||
| AML, M2 (S. M.) | + | 0.29 | 42.1 | 29.9 | 20.0 |
| AML, M2 (M. M.) | + | 0.23 | 29.3 | 19.9 | 11.1 |
| AML, M2 (I. K.) | + | 0.47 | 51.7 | 43.3 | 36.2 |
| AML, M4 (K. O.) | + | 0.22 | 39.7 | 24.7 | 18.8 |
| AML, M4 (T. F.) | + | 0.19 | 40.3 | 32.9 | 27.5 |
| AML, M5 (T. O.) | + | ND | 15.4 | 10.5 | 7.0 |
| AML, M5 (F. O.) | + | 0.15 | 0.9 | 0.9 | 0.1 |
| ALL, L2 (K. I.) | + | ND | 32.1 | 27.3 | 13.5 |
| ALL, L2 (M. H.) | + | 0.34 | 3.9 | 1.1 | 0.8 |
| AML, M2 (E. O.) | − | <0.01 | 0.1 | 0.8 | 0 |
| AML, M3 (S. N.) | − | ND | 2.9 | 0.5 | 1.2 |
| AML, M4 (K. N.) | − | 0.30 | 0.7 | 0.4 | 0.9 |
| AML, M5 (M. O.) | − | 0.29 | 1.8 | 1.0 | 0.5 |
| ALL, L1 (N. Y.) | − | 0.43 | 1.5 | 0.5 | 1.0 |
| ALL, L2 (T. M.) | − | 0.32 | 1.3 | 0.5 | 0.2 |
| ALL, L2 (Y. I.) | − | ND | 0.4 | 0.5 | 1.3 |
| Normal foreskin fibroblasts | |||||
| #1 (A. S.) | + | <0.01 | 0.8 | 0.6 | 0.2 |
| #2 (T. A.) | + | <0.01 | 1.6 | 0.9 | 1.1 |
| #3 (Y. N.) | + | <0.01 | 0.7 | 1.0 | 0.4 |
| #4 (N. G.) | − | <0.01 | 0.2 | 0.7 | 1.2 |
| #5 (M. Y.) | − | <0.01 | 0.8 | 0 | 1.9 |
| Normal PBMCs | |||||
| #1 (H. O.) | + | <0.01 | 0.6 | 0.5 | 0.1 |
| #2 (J. A.) | + | <0.01 | 1.4 | 0.2 | 0.8 |
| #3 (T. N.) | − | <0.01 | 0.1 | 0.5 | 0.7 |
ND indicates not determined.
The WT1 mRNA expression levels are expressed as WT1 mRNA/GAPDH mRNA intensity ratios quantified by densitometric analysis.
The cytotoxicity of TAK-1 to various freshly isolated leukemia cells, normal foreskin fibroblasts, and normal PBMCs in the absence of the WT1-peptide was determined by 4-hour 51Cr release assays at E:T ratios of 10:1, 5:1, and 2.5:1.